Qianjiang Yong'an Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
On April 29, 2026, and May 27, 2026, the Company held the 15th meeting of the 7th Board of Directors and the 2025 Annual General Meeting, respectively, where the proposal for changing the business scope and amending the Articles of Association was approved. Specific details can be found in the Company's announcements disclosed on the designated information disclosure media of the China Securities Regulatory Commission, including the "Announcement of the Resolutions of the 15th Meeting of the 7th Board of Directors" (Announcement No. 2026-22), "Announcement on Changing the Business Scope and Amending the Articles of Association" (Announcement No. 2026-25), and "Announcement of the Resolutions of the 2025 Annual General Meeting" (Announcement No. 2026-29).
Recently, the Company has completed the registration of changes to its business scope and the filing procedures for the Articles of Association, and has obtained a new business license reissued by the Hubei Provincial Market Supervision Administration. The specific details are as follows: